Giant Congenital Melanocytic Nevus
NORD is very grateful to Harper Price, MD, Department of Dermatology, Phoenix Children’s Hospital, and Heather Etchevers, PhD, National Institutes for Health and Medical Research of France (INSERM), for the preparation of this report.
Synonyms of Giant Congenital Melanocytic Nevus
- bathing trunk nevus
- cape nevus
- congenital pigmented nevus
- garment nevus
- giant brown birthmark
- giant hairy nevus
- giant hairy pigmented nevus
- giant mole
- giant nevus
- hairy birthmark
- leptomeningeal melanosis
- multiple congenital melanocytic nevi
- neurocutaneous melanocytosis
- neurocutaneous melanosis
- satellite nevi
- swimming trunk nevus
- No subdivisions found.
Congenital melanocytic nevi (CMN) are visible pigmented (melanocytic) proliferations in the skin that are present at birth. CMN are benign, tumor-like malformations resulting from faulty development of pigment cell (melanocyte) precursors in the embryo, and composed of an abnormal mixture of skin elements. Defined areas of these melanocytic proliferations cover surfaces at the base of the epidermis ranging from a few millimeters in diameter to large sectors of the body. In the larger forms, the CMN (single or multiple) also extend(s) vertically into the deeper dermis and more rarely, into the hypodermis or even subcutaneous tissues. The most superficial component of the CMN is the most highly pigmented, conferring brown-to-black shades to the overlying epidermis. CMN are usually classified according to their predicted largest diameter in adulthood, as if they were circular (predicted adult diameter or PAS). The most used classification assigns small CMN as less than 1.5 cm PAS, medium sized CMN between 1.5 to 19.9 cm, and large CMN 20 cm or greater. CMN measuring 50 cm or larger in PAS have been referred to as ‘giant congenital melanocytic nevi’.
CMN can be light brown to black patches or plaques, can present in variable ways, and cover nearly any size surface area or any part of the body. The incidence of CMN seems to be independent of skin color or other ethnic factors. Small to medium CMN are predicted to occur in more than one in a hundred births. Large and especially giant CMN, exceeding a predicted diameter at adult age of at least 20 cm on the body, form a much rarer subset, with prevalence estimated at around 1 in 50,000 births. Non-pigmented or small incipient congenital lesions can also be present - these are known as "tardive"; the emergence of so-called "satellite" nevi throughout the first few years of life in conjunction with larger CMN probably reflects the postnatal maturation of such precursors. On occasion, even a primary CMN can appear in a tardive manner. Treatment options currently are exclusively surgical. Neurocutaneous melanocytosis, cited in earlier literature as neurocutaneous melanosis (NCM), is a neurological and cutaneous disorder characterized by abnormal aggregations of nevomelanocytes within the central nervous system and the skin. NCM is a complication of the larger forms of CMN, or multiple smaller CMN, in a fraction of patients. Recent studies find the incidence of symptomatic and asymptomatic NCM together to range between 5 and 15 % of all persons with large and giant CMN. Melanoma develops in an estimated 1-2% of patients with LCMN or NCM, more frequently and at earlier ages than in the general population.
The first recorded descriptions of children with large CMN date from observations published by the Count of Buffon before the French Revolution. Other giant, sometimes rugous CMN were described in the early 19th century.
CMN tend to grow in a proportional fashion to the child’s growth; occasionally growth appears out of proportion to the child during periods of particularly rapid growth such as early infancy. A new size/color/texture classification, recently developed by Marghoob, Krengel and other experts in the field, may eventually help in better predicting patients at the greatest risk for developing melanoma or neurological disease by more reproducibly classifying similar patients. Nomograms can assist clinicians in easily determining the PAS of a nevus examined at any point during childhood.
Large/giant CMN are obvious at birth, most commonly covering an aspect of the trunk and less common on the head, neck and extremities. Affected areas of large CMN have been designated as "cape", "bathing trunk", "tippet" or "garment" CMN due to their respective distributions. Lesions may have irregular or geographic borders. In about 75% of cases, multiple small CMN will accompany the large CMN, usually in a generalized manner. "Satellite" is a commonly used description of discrete small or medium CMN or tardive nevi in the presence of a large/giant CMN, though semantically and molecularly, it is more accurate to refer to "disseminated" lesions. These additional smaller, disseminated CMN may be present at birth and/or may increase to significant numbers over the first few years of life. These multiple CMN should be noted in number, as greater numbers (>20) have been correlated with neurological anomalies.
In general, CMN can be tan, brown to dark-brown or black and rarely blue in color and may be flat, raised, or even quite thickened at birth. Color may be quite uniform throughout, or consist of multiple colors including shades of brown, black, red or blue. Texture may be smooth, highly nodular or cobblestone-like; hair may or may not be present at birth and may or may not develop as the child ages. This hair is fine (vellus) or more often coarse (terminal) in texture. A "cerebriform" or brain-like texture may be present, particularly in large scalp CMN. Areas of the nevus may be infiltrated by overgrowths of fatty or nerve tissue, so-called lipomatous or neurotized areas respectively, features that can be seen most often in larger CMN.
Over time, CMN may become darker or lighter, more or less heterogenous in color and the surface texture may change. CMN can also develop superimposed nodules, which are usually benign but require surveillance. The CMN-involved skin can be dry and develop overlying eczema, resulting in intermittent or chronic itchiness (pruritis). CMN may also have fewer sweat glands than unaffected skin, resulting in potential overheating episodes or increased sweating in other areas of the body to compensate. Areas of larger CMN may have notably less fat under the skin, particularly around the flanks, limbs and buttocks.
At birth or within the first few weeks of life, transient erosions or ulcerations may develop over large CMN due to incomplete maturation of the skin during this period. Healing usually occurs over days to weeks. Also notable during the infantile period are rapidly growing ‘proliferative nodules’ within the CMN that mimic melanoma but show benign features when examined. Evaluation of these nodules by a dermatopathologist with expertise in pigmented lesions is recommended to avoid unnecessary surgery and possible toxic adjuvant therapy if misdiagnosed as melanoma. Significant lightening of color in large CMN can also been seen in the first few years of life, especially those that involve the scalp.
Both CMN and acquired melanocytic nevi are associated with somatic mutations in intracellular proteins of the microtubule-associated protein signal transduction pathway. For 4 in 5 cases, a single mutation in the DNA encoding the NRAS enzyme can be found, and for up to one in 6 cases, a single mutation in the DNA for the BRAF enzyme. The currently identified mutations cause the enzymes to become permanently active, and have been found in many apparently unrelated cancers as well, perhaps driving cells to proliferate. These findings imply that other, less common and not yet identified, mutations may also contribute to cause CMN.
Both CMN and normal pigment cells (melanocytes) come from an embryonic cell population that separates from the future central nervous system before the end of the first month of pregnancy, and as it multiplies, the population colonizes all the tissues of the body. Within the skin, these cells then become pigment cell precursors that are both between and at the base of hair follicles. Constant activation of NRAS or BRAF may drive the prenatal proliferation of this cell population. A second mutation that occurs in the other copy of the NRAS or BRAF gene in a CMN cell may be responsible for the onset of malignant melanoma, which happens more frequently in children affected with large/giant CMN than in the general pediatric population, where melanoma is exceedingly rare. Recent results indicate that the same NRAS mutations may also be responsible for nevomelanocyte proliferation within the central nervous system, causing NCM.
Large/giant CMN are usually sporadic, but familial occurrence has been rarely reported. One of the first reports that families of patients with giant CMN had relatives with multiple small pigmented nevi was made over 40 years ago, and this observation has been made many times since. Affected siblings and first cousins have also been observed. Autosomal dominant inheritance with reduced penetrance and/or multifactorial inheritance are possible explanations for the familial cases.
Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary to cause the disease. The gene can be inherited from either parent or can be the result of a new mutation (gene change) in the affected individual. Some individuals who have the abnormal gene may not display symptoms of the condition (reduced penetrance).
Multifactorial inheritance means that many factors, including a combination of genes from both parents, in addition to unknown environmental factors, cause the condition.
People of all races and colors of skin can be affected with large/giant CMN. A slight female preponderance has been noted in large/ giant CMN (male/female ratio of 1 to 1.4), but is not observed in the smaller population of people affected by NCM.
Neurocutaneous melanocytosis is present in an estimated 5-15% of patients with large/giant CMN, while melanoma can occur in an estimated 1-2%.
The development of melanoma is a significant complication in people with large/giant CMN. The risk of melanoma development (cutaneous or extracutaneous) in large CMN is at the most 5% over a lifetime, considering prospective and retrospective cohort studies with significant follow-up, and seemingly independent of ethnicity. About half of these melanomas occur in the first 5 years of life. Cutaneous melanomas tend to arise deep in the skin or residual fatty tissues of a large CMN, making early detection difficult. Melanomas may also arise in other non-cutaneous areas such as the brain, and sometimes the primary location of melanoma is not found. Other malignancies such as liposarcomas, rhabdomyosarcomas and malignant peripheral nerve sheath tumors have been described in association with large CMN. No reliable case of melanoma arising within an associated small CMN has yet been reported.
Neurocutaneous melanocytosis and central nervous system malformations:
In addition to melanoma, patients with large CMN and multiple medium CMN are also at risk for developing neurocutaneous melanocytosis (NCM), estimated to occur in 7% of individuals born with large CMN. NCM is a proliferation of pigment cells in the leptomeninges or brain parenchyma due to abnormal migration or differentiation of their precursors, which normally invest these tissues to become mostly vascular pericytes with a few melanocytes. Rokitansky is credited with the first description of NCM in a teenaged girl with hydrocephalus, giant CMN and developmental delay, complete with autopsy after her death from tuberculosis, that confirmed the meningeal melanocytosis.
Although pigmented deposits are generally benign, symptoms such as hydrocephalus and seizures indeed can occur, or intracerebral melanoma develops in a small proportion of cases. NCM has been classically defined by Kadonaga and Frieden as the co-existence of large or multiple CMN (>3) in association with meningeal melanocytosis or melanoma, with no evidence of cutaneous melanoma, except in patients whom the examined areas of the meningeal lesions are histologically benign.
Magnetic resonance imaging (MRI) with contrast of the brain and spine may be recommended for any individual with multiple CMN, or a large CMN with > 20 "satellite" nevi, as those with 20 or more disseminated nevi are 5 more times likely to have NCM than those with less. Individuals with giant CMN > 40cm PAS, or those with a CMN over the posterior axis (according to some authors) may also be at increased risk for NCM. Only about 4% of these ‘high-risk’ CMN individuals will develop symptomatic NCM; for these, prognosis can be poor, even without melanoma development, although many symptomatic patients survive with various neurological deficits.
Ideally, MRI should be done in the first 4-6 months of life, prior to full myelinization of the brain, which may obscure the melanin signal. Technical suggestions by an experienced radiologist in demonstrating NCM are available at this link: http://www.nevus.org/page_file_download.php?id=30 (accessed Jan. 30, 2013).
Based on previous studies, approximately half of those individuals with NCM will become symptomatic, often before the age of 5. Patients can present with hydrocephalus or other signs indicating increased cranial pressure, such as headaches and vomiting, or seizures. Mild to severe developmental delay and abnormal tone have also been described in children with high-risk CMN. Asymptomatic NCM (positive MRI without clinical symptoms attributed to NCM) has been diagnosed in up to 30% of patients with supposedly high risk CMN, and the percentage of patients that may eventually develop symptoms from NCM is currently unknown. Epilepsy can be responsive or refractory to standard medications and also can be treated favorably by surgical approaches used in other forms of epilepsy.
Other CNS tumors and malformations found often incidentally during brain and spine imaging of CMN patients have included Dandy-Walker malformations, lissencephaly, Chiari I malformations, posterior fossa cysts, spinal and other lipomas, arachnoid cysts and tethered spinal cord.
The differential diagnosis of small and medium CMN includes smooth muscle hamartoma or Becker’s nevus, mastocytoma, variants of dermal melanocytosis, and café au lait macules. Large CMN may be confused with a pigmented, plexiform neurofibroma. Histologic evaluation, dermoscopic evaluation and the development of typical CMN features over time may clarify the diagnosis.
Making the diagnosis of a CMN is most often done by examining clinical and dermoscopic features. The larger CMN can easily be diagnosed based solely on their size. For smaller CMN, their history of presence since birth, surface topography, presence of hair or globular dermoscopic pattern can assist in diagnosis. When biopsied, the histological features of CMN are similar to those found in common acquired nevi which arise later in life; however, CMN tend have a greater cellularity with deeper extension of nevus cells into the deep dermis and subcutis, and cells extend along adnexal structures such as hair follicles and around blood vessels and nerves. Histological criteria alone cannot be used to dictate with absolute certainty whether a nevus is congenital or acquired.
Clinical Testing and Workup
Magnetic resonance imaging (MRI) with contrast of the brain and spine is recommended for any individual with multiple CMN, or a large CMN with > 20 satellite nevi, as those with 20 or more satellite nevi are 5 more times likely to have NCM than those with fewer, and some of these will become symptomatic. Any patient with new onset of neurological symptoms, such as enuresia (extended night-time bed-wetting) or tiptoeing which indicate the possibility of a tethered spinal cord, epilepsy, or "sunset eyes" (indicative of increased intracranial pressure due to hydrocephalus) should also undergo a neurologic evaluation and appropriate imaging. Patients with asymptomatic NCM should also be followed by a neurologist, on a yearly basis or more frequently if concerns exist. The need for subsequent MRIs in those asymptomatic patients is not clear; however, most experts will not recommend further MRI unless symptoms arise. Patients with significant symptomatic NCM should consider foregoing elective surgical removal of the CMN until prognosis is clear.
Lifelong monitoring in patients with extensive CMN is mandatory regardless of the treatment employed, both with self-skin examinations and in an experienced dermatologist’s office. Serial photographs, the use of dermoscopy, palpation of nevus and scars, examination of lymph nodes and a thorough review of systems may aid physicians in early detection of melanoma. Suspicious lesions should be removed and examined histologically by an experienced pathologist.
Treatments currently rely on the arsenal of plastic surgical techniques. While partial-thickness grafts or ablations, using dermabrasion or curettage, have been used in the past and are still occasionally relevant, the gold standard is to replace the skin in its full thickness. Replacement skin can be generated from other zones by natural forced expansion from adjacent areas, or implanting expanders either adjacent to or in a donor graft site. Artificial dermis is currently an inadequate replacement for most nevi. Simple surveillance is an option for extensive, technically inaccessible and homogeneous nevi. Psychological accompaniment is highly recommended for both patients and families, irrespective of physical treatment options. Each treatment regimen is unique as a result of the highly individual distributions and combinations of textures, nodules and other attributes of CMN.
Information on current clinical trials is posted on the Internet at http://www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry or foreign governments, are posted on this web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office (http://www.cc.nih.gov/recruit/) tollfree: (800) 411-1222 TTY: (866) 411-1010 E-mail: email@example.com
For information about other clinical trials sponsored by private sources, contact: www.centerwatch.com
For information about clinical trials conducted in Europe, contact:
Giant Congenital Melanocytic Nevus Resources
Reyes-Múgica, M., Beckwith, M. and Etchevers, H. C. (2012). Etiology of Congenital Melanocytic Nevi and Related Conditions. In Nevogenesis (Practical Clinical Medicine series) (ed. Marghoob, A. A.), pp. 73-97. Berlin, Heidelberg: Springer Berlin Heidelberg.
Zalaudek, I., Longo, C., Ricci, C., Albertini, G. and Argenziano, G. (2012). Classifying Melanocytic Nevi. In Nevogenesis (Practical Clinical Medicine series) (ed. Marghoob, A. A.), pp. 25-41. Berlin, Heidelberg: Springer Berlin Heidelberg.
Bolognia, J.L., Jorizzo, J.L. and Schaffer, J.V. (2012) Dermatology:3rd Edition. 2776 pages. ISBN: 978-0-7234-3571-6.
Agero, A. L. C., Benvenuto-Andrade, C., Dusza, S. W., Halpern, A. C. and Marghoob, A. (2005). Asymptomatic neurocutaneous melanocytosis in patients with large congenital melanocytic nevi: a study of cases from an Internet-based registry. Journal of the American Academy of Dermatology 53, 959-65.
Ahmed, I., Tope, W. D., Young, T. L., Miller, D. M. and Bloom, K. E. (2002). Neurocutaneous melanosis in association with encephalocraniocutaneous lipomatosis. Journal of the American Academy of Dermatology 47, S196-S200.
Alibert, J.-L. (Baron) (1835). Monographie des Dermatoses, ou Précis théorique et pratique des maladies de la peau. 2nd ed. Paris: Bailliere, G.
Bauer, J., Curtin, J. A., Pinkel, D. and Bastian, B. C. (2007). Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. The Journal of investigative dermatology 127, 179-82.
Bett, B. J. (2005). Large or multiple congenital melanocytic nevi: occurrence of cutaneous melanoma in 1008 persons. Journal of the American Academy of Dermatology 52, 793-7.
Bett, B. J. (2006). Large or multiple congenital melanocytic nevi: occurrence of neurocutaneous melanocytosis in 1008 persons. Journal of the American Academy of Dermatology 54, 767-77.
Castilla, E. E., Da Graça Dutra, M. and Orioli-Parreiras, I. M. (1981). Epidemiology of congenital pigmented naevi: I. Incidence rates and relative frequencies. The British Journal of Dermatology 104, 307-15.
Chan, Y.-C. and Giam, Y.-C. (2006). A retrospective cohort study of Southeast Asian patients with large congenital melanocytic nevi and the risk of melanoma development. Journal of the American Academy of Dermatology 54, 778-82.
DeDavid, M., Orlow, S. J., Provost, N., Marghoob, A. A., Rao, B. K., Huang, C. L., Wasti, Q., Kopf, A. W. and Bart, R. S. (1997). A study of large congenital melanocytic nevi and associated malignant melanomas: review of cases in the New York University Registry and the world literature. Journal of the American Academy of Dermatology 36, 409-16.
Dessars, B., De Raeve, L. E., El Housni, H., Debouck, C. J., Sidon, P. J., Morandini, R., Roseeuw, D., Ghanem, G. E., Vassart, G. and Heimann, P. (2007). Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi. The Journal of Investigative Dermatology 127, 1468-70.
Dessars, B., De Raeve, L. E., Morandini, R., Lefort, A., El Housni, H., Ghanem, G. E., Van den Eynde, B. J., Ma, W., Roseeuw, D., Vassart, G., et al. (2009). Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. The Journal of Investigative Dermatology 129, 139-47.
Egan, C. L., Oliveria, S. A., Elenitsas, R., Hanson, J. and Halpern, A. C. (1998). Cutaneous melanoma risk and phenotypic changes in large congenital nevi: a follow-up study of 46 patients. Journal of the American Academy of Dermatology 39, 923-32.
Etchevers, H. C., Vincent, C., Le Douarin, N. M. and Couly, G. F. (2001). The cephalic neural crest provides pericytes and smooth muscle cells to all blood vessels of the face and forebrain. Development 128, 1059-68.
Foster, R. D., Williams, M. L., Barkovich, A. J., Hoffman, W. Y., Mathes, S. J. and Frieden, I. J. (2001). Giant congenital melanocytic nevi: the significance of neurocutaneous melanosis in neurologically asymptomatic children. Plastic and Reconstructive Surgery 107, 933-41.
Frieden, I. J., Williams, M. L. and Barkovich, A. J. (1994). Giant congenital melanocytic nevi: brain magnetic resonance findings in neurologically asymptomatic children. Journal of the American Academy of Dermatology 31, 423-9.
Giam, Y. C., Williams, M. L., Leboit, P. E., Orlow, S. J., Eichenfield, L. F. and Frieden, I. J. (1999). Neonatal erosions and ulcerations in giant congenital melanocytic nevi. Pediatric Dermatology 16, 354-8.
Gonzalez, J., Palangio, M., Fialkoff, C. N., Schwartz, J. and Bisaccia, E. (2003). Giant congenital melanocytic nevus with a large ulceration at birth: a 5-year follow-up. Journal of the American Academy of Dermatology 49, 752-4.
Goodman, R. M., Caren, J., Ziprkowski, M., Padeh, B., Ziprkowski, L. and Cohen, B. E. (1971). Genetic considerations in giant pigmented hairy naevus. The British Journal of Dermatology 85, 150-7.
Gulati, R., Jain, D., Mehrania, K., Kuldeep, C. M. and Mathur, D. (2000). Giant congenital nevomelanocytic nevus with satellite lesions, vitiligo and lipoma?: a rare association. Indian Journal of Dermatology, Venereology and Leprology 66, 316-7.
Hale, E. K., Stein, J., Ben-Porat, L., Panageas, K. S., Eichenbaum, M. S., Marghoob, A. A., Osman, I., Kopf, A. W. and Polsky, D. (2005). Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi - results from the NYU-LCMN registry. Br J Dermatol 152, 512-517.
Hecht, F., LaCanne, K. M. and Carroll, D. B. (1981). Inheritance of giant pigmented hairy nevus of the scalp. American Journal of Medical Genetics 9, 177-8.
Kadonaga, J. N. and Frieden, I. J. (1991). Neurocutaneous melanosis: definition and review of the literature. Journal of the American Academy of Dermatology 24, 747-55.
Kanada, K. N., Merin, M. R., Munden, A. and Friedlander, S. F. (2012). A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. The Journal of Pediatrics 161, 240-5.
Kinsler, V. (2011). Satellite lesions in congenital melanocytic nevi-time for a change of name. Pediatric Dermatology 28, 212-3.
Kinsler, V. A., Chong, W. K., Aylett, S. E. and Atherton, D. J. (2008). Complications of congenital melanocytic naevi in children: analysis of 16 years’ experience and clinical practice. The British Journal of Dermatology 159, 907-14.
Kinsler, V. A., Birley, J. and Atherton, D. J. (2009). Great Ormond Street Hospital for Children Registry for congenital melanocytic naevi: prospective study 1988-2007. Parts 1 and 2. The British Journal of Dermatology 160, 143-50 and 387-392.
Kinsler, V. A., Thomas, A. C., Ishida, M., Bulstrode, N. W., Loughlin, S., Hing, S., Chalker, J., McKenzie, K., Abu-Amero, S., Slater, O., et al. (2013). Multiple congenital melanocytic naevi and neurocutaneous melanosis are caused by post-zygotic mutations in codon 61 of NRAS. Journal of Investigative Dermatology doi:10.1038/jid.2013.70; accepted article preview online February 7, 2013.
Krengel, S., Hauschild, A., Schäfer, T. and Schafer, T. (2006). Melanoma risk in congenital melanocytic naevi: a systematic review. British Journal of Dermatology 155, 1-8.
Krengel, S., Breuninger, H., Beckwith, M. and Etchevers, H. C. (2011). Meeting report from the 2011 international expert meeting on large congenital melanocytic nevi and neurocutaneous melanocytosis, Tübingen. Pigment Cell & Melanoma Research 24, E1-6.
Krengel, S., Scope, A., Dusza, S. W., Vonthein, R. and Marghoob, A. A. (2012). New recommendations for the categorization of cutaneous features of congenital melanocytic nevi. Journal of the American Academy of Dermatology 68, 441-51.
Leclerc, G.-L. (Comte de Buffon. (1777). Tome XXXIII (Supplément IV). In Histoire Naturelle Générale et Particulière?: avec la description du Cabinet du Roy., p. 582. Paris.
Lovett, A., Maari, C., Decarie, J.-C., Marcoux, D., McCuaig, C., Hatami, A., Savard, P. and Powell, J. (2009). Large congenital melanocytic nevi and neurocutaneous melanocytosis: one pediatric center’s experience. Journal of the American Academy of Dermatology 61, 766-74.
Mancianti, M. L., Clark, W. H., Hayes, F. A. and Herlyn, M. (1990). Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype. The American Journal of Pathology 136, 817-29.
Marghoob, A. , Dusza, S., Oliveria, S. and Halpern, A. C. (2004). Number of satellite nevi as a correlate for neurocutaneous melanocytosis in patients with large congenital melanocytic nevi. Archives of dermatology 140, 171-5.
Phadke, P. A., Rakheja, D., Le, L. P., Selim, M. A., Kapur, P., Davis, A., Mihm, M. C. and Hoang, M. P. (2011). Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases. The American Journal of Surgical Pathology 35, 656-69.
Price, H. N. and Schaffer, J. V (2010). Congenital melanocytic nevi-when to worry and how to treat: Facts and controversies. Clinics in Dermatology 28, 293-302.
Ramaswamy, V., Delaney, H., Haque, S., Marghoob, A. and Khakoo, Y. (2012). Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis. Developmental Medicine and Child Neurology 54, 563-8.
Rhodes, A. R., Albert, L. S. and Weinstock, M. A. (1996). Congenital nevomelanocytic nevi: proportionate area expansion during infancy and early childhood. Journal of the American Academy of Dermatology 34, 51-62.
Rokitansky, J. (1861). Ein ausgezeichneter Fall von Pigment-mal mit ausgebreiteter Pigmentierung der inneren Hirn- und Ruchenmarkshaute. Allg Wien Med Z 6, 113-6.
Rolleston, J. D. (1915). Giant Naevus. Proceedings of the Royal Society of Medicine 8, 11-5.
Schaffer, J. V, Chang, M. W., Kovich, O. I., Kamino, H. and Orlow, S. J. (2007). Pigmented plexiform neurofibroma: Distinction from a large congenital melanocytic nevus. Journal of the American Academy of Dermatology 56, 862-8.
Schallreuter, K. U., Levenig, C. and Berger, J. (1991). Vitiligo and cutaneous melanoma. A case study. Dermatologica 183, 239-45.
Shah, K. N. (2010). The risk of melanoma and neurocutaneous melanosis associated with congenital melanocytic nevi. Seminars in Cutaneous Medicine and Surgery 29, 159-64.
Tromberg, J., Bauer, B., Benvenuto-Andrade, C. and Marghoob, A. A. (2005). Congenital melanocytic nevi needing treatment. Dermatologic Therapy 18, 136-50.
Voigtländer, V. and Jung, E. G. (1974). Giant pigmented hairy nevus in two siblings. Humangenetik 24, 79-84.
Vourc'h-Jourdain M., Martin L., Barbarot S.;ED and the Association Recommandations En Dermatologie (aRED). (2013). Large congenital melanocytic nevi: Therapeutic management and melanoma risk: A systematic review. Journal of the American Academy of Dermatology 68, 493-498.e14.
DermNet NZ: information from the the New Zealand Dermatological Society. "Congenital Melanocytic Naevi". Last updated:Jan 23, 2013. Available at: http://dermnetnz.org/lesions/congenital-naevus.html Accessed:January 30, 2013.
McCalmont, T. Melanocytic Nevi. Last updated: Aug 12, 2011. Available at:
Accessed:January 30, 2013
Etchevers, H. Large congenital melanocytic nevus. Orphanet Entry No: ORPHA626 Last updated:January, 2011. Available at: http://bit.ly/RcPS4G Accessed:January
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
Report last updated: 2013/02/14 00:00:00 GMT+0
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.